Browsing Tag

Partnering

580 posts

AstraZeneca, Daiichi Sankyo Enter $6-Bn Pact for Antibody Drug Conjugate
By

By
AstraZeneca has entered into a global development and commercialization agreement with Daiichi Sankyo, in a deal worth up to $6 billion, for DS-1062, Daiichi Sankyo’s antibody drug conjugate (ADC) for…

Pharma COVID Roundup: News from AstraZeneca, CanSino, Celltrion
By

By
The latest on manufacturing and potential treatments for COVID-19 with news from AstraZeneca, CanSino Biologics, CGT Catapult, Bharat Biotech, and Celltrion. AstraZeneca Reports Promising Early-Trial Results of COVID-19 VaccineAstraZeneca reports…

GSK, CureVac in $1.1-Bn Pact for mRNA Vaccines and mAbs
By

By
GlaxoSmithKline (GSK) and CureVac, a Tubingen, Germany-based clinical-stage biopharmaceutical company developing a messenger ribonucleic acid (mRNA) therapeutics, have signed a strategic collaboration agreement, in a deal worth up to £866…

Pfizer, BioNTech in $1.95-Bn Deal with US Gov’t for COVID-19 Vaccine
By

By
Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, have entered an agreement with the US Department of Health and Human Services and the Department of Defense, in a deal worth…

Global Pharma Briefs: News from Europe and the US
By

By
A roundup of news from Switzerland (BI, Numab Therapeutics) and the US (Bayer, Elanco, Mylan, Merck & Co, Dewpoint Therapeutics, and Nephron Pharmaceuticals). Switzerland BI, Numab Therapeutics in Pact for…

Roche, Blueprint in $1.7-Bn Deal for Targeted Cancer Drugs
By

By
Roche and Blueprint Medicines, a Cambridge, Massachusetts-based biopharmaceutical company, have signed a licensing and collaboration agreement, in a deal worth up to $1.7 billion, to develop and commercialize pralsetinib, an…

Blackstone Launches $4.6-Bn Life Sciences Fund
By

By
Blackstone, a private investment firm, has closed on its first fund in the life sciences, Blackstone Life Sciences, with $4.6 billion in total capital commitments. The fund is focused on…

Pharma Companies in Pact To Invest $1 Bn in AMR Action Fund
By

By
More than 20 biopharmaceutical companies have announced their participation in the AMR Action Fund to support research of new antibiotics to address the rise of antibiotic-resistant infections, also called antimicrobial…

Sanofi, Kymera in $2.15-Bn Pact to Advance Protein-Degrader Therapies
By

By
Sanofi and Kymera Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company, have entered into a multi-program strategic collaboration to develop and commercialize protein-degrader therapies for immune-inflammatory diseases, in a deal worth up…

Sanofi, Kiadis in $996-M Deal for Natural-Killer Cancer Programs
By

By
Sanofi and Kiadis Pharma, an Amsterdam-based clinical-stage company developing therapeutics based on natural killer (NK) cells, have entered into an exclusive license agreement, in a deal worth up to EUR…